Marc Duey - Oct 18, 2024 Form 4 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
Director
Signature
/s/ John P. Hamill, as Attorney-in-Fact
Stock symbol
APRE
Transactions as of
Oct 18, 2024
Transactions value $
-$29,583
Form type
4
Date filed
10/25/2024, 05:42 PM
Previous filing
Oct 17, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APRE Common Stock Sale -$29.6K -6.46K -2.69% $4.58 234K Oct 18, 2024 Direct F1, F2
holding APRE Common Stock 602 Oct 18, 2024 By Spouse F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person's sale of Issuer's common stock reported herein was automatically transacted by the Reporting Person's broker as a result of an insufficient cash position in the Reporting Person's brokerage account. Further, the Reporting Person's sale of Issuer's common stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934 (i) to the extent of 190 shares, with the Reporting Person's purchase of 190 shares of the Issuer's common stock at a price of $2.5837 on October 14, 2024, and (ii) to the extent of 6,272 shares, with the Reporting Person's purchase of 30,000 shares of the Issuer's common stock at a price of $4.39 per share on October 16, 2024. The Reporting Person has agreed to pay to Issuer $1,558.05 which represents the full amount of the profit realized in connection with the short-swing transaction.
F2 These shares were sold in multiple transactions on October 18, 2024, each at $4.578 per share.
F3 The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.